Glycoprotein IIb/IIIa inhibitors
| Cardiology Network |
 Discuss Glycoprotein IIb/IIIa inhibitors further in the WikiDoc Cardiology Network |
| Adult Congenital |
|---|
| Biomarkers |
| Cardiac Rehabilitation |
| Congestive Heart Failure |
| CT Angiography |
| Echocardiography |
| Electrophysiology |
| Cardiology General |
| Genetics |
| Health Economics |
| Hypertension |
| Interventional Cardiology |
| MRI |
| Nuclear Cardiology |
| Peripheral Arterial Disease |
| Prevention |
| Public Policy |
| Pulmonary Embolism |
| Stable Angina |
| Valvular Heart Disease |
| Vascular Medicine |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [3] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Glycoprotein IIb/IIIa inhibitors, also GpIIb/IIIa inhibitors, are a class of antiplatelet agents.
Several GpIIb/IIIa inhibitors exist:
- Abciximab (ReoPro®)
- Eptifibatide (Integrilin®)
- Tirofiban (Aggrastat®)
Use
Glycoprotein IIb/IIIa inhibitors are frequently used during percutaneous coronary interventions (angioplasty with or without intracoronary stent placement).
They work by preventing platelet aggregation and thrombus formation. They do so by inhibition of the GpIIb/IIIa receptor on the surface of the platelets. By blocking the GPIIbIIIa receptor, they block the ability of platelets to cross link via fibrinogen.
The agents in this class are administered intravenously. Oral forms of these agents were associated with increased mortality, possibly due to underdosing of the agents.
History
Their development arose from the understanding of Glanzmann's thrombasthenia, a condition in which the GpIIb/IIIa is lacking.[1]
Reference
- ↑ Seligsohn U. Glanzmann thrombasthenia: a model disease which paved the way to powerful therapeutic agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):216-7. PMID 13679645. Free Full Text.